#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	3938	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2376	488.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1621	1621	C	574	C	483	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6168	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3924	470.2	0	.	n	.	0	T695C	SNP	695	695	T	1175	1175	C	448	C,A	375,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6168	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3924	470.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1817	1817	A	482	A,T,G,C	411,1,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6168	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3924	470.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2451	2451	C	571	C,A	488,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6168	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3924	470.2	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3077	3077	T	582	T,G	489,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6168	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3924	470.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2525	2525	A	622	A,T	523,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6168	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3924	470.2	0	HET	.	.	.	G495A,T	.	495	495	G	975	975	G	481	G,A,T	319,77,1	.	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	594	folP	852	852	100.0	folP.l6.c4.ctg.1	1840	96.1	1	SNP	p	R228S	1	.	.	682	684	AGC	1180	1182	AGC	137;137;137	A;G;C,A	120;121;120,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1322	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3811	103.7	1	SNP	p	S91F	0	.	.	271	273	TCC	750	752	TCC	124;125;124	T;C;C,T	102;107;105,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1322	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3811	103.7	1	SNP	p	D95N	0	.	.	283	285	GAC	762	764	GAC	122;120;121	G;A,G;C	107;103,1;107	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1322	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3811	103.7	1	SNP	p	D95G	0	.	.	283	285	GAC	762	764	GAC	122;120;121	G;A,G;C	107;103,1;107	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	572	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1694	101.0	0	.	p	.	0	A39T	NONSYN	115	117	GCC	617	619	ACC	151;151;152	A,G;C;C	131,1;135;133	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	572	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1694	101.0	0	.	p	.	0	R44H	NONSYN	130	132	CGC	632	634	CAC	149;151;151	C;A,G;C	129;130,1;134	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	572	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1694	101.0	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	815	817	CAC	154;151;151	C;A;C	130;131;128	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	572	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1694	101.0	1	SNP	p	G45D	0	.	.	133	135	GGC	635	637	GGC	152;153;153	G;G;C	135;130;134	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	386	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c4.ctg.1	1254	91.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1314	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3422	114.9	1	SNP	p	D86N	0	.	.	256	258	GAC	892	894	GAC	150;148;149	G;A;C	126;126;130	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1314	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3422	114.9	1	SNP	p	S87W	0	.	.	259	261	AGT	895	897	AGT	151;151;152	A,C;G;T	125,1;129;127	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1314	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3422	114.9	1	SNP	p	S87R	0	.	.	259	261	AGT	895	897	AGT	151;151;152	A,C;G;T	125,1;129;127	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1314	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3422	114.9	1	SNP	p	S87I	0	.	.	259	261	AGT	895	897	AGT	151;151;152	A,C;G;T	125,1;129;127	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1314	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3422	114.9	1	SNP	p	S88P	0	.	.	262	264	TCC	898	900	TCC	152;151;150	T,G;C;C	129,1;128;132	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1174	parE	1986	1986	100.0	parE.l6.c17.ctg.1	3118	112.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1866	1868	GGC	153;153;152	G;G;C	130;125;119	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	994	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2759	107.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1522	1524	GCA	136;137;136	G,T;C;A	107,1;108;110	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	994	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2759	107.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1525	1527	ATC	134;134;134	A;T,G;C	109;106,1;108	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	994	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2759	107.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1537	1539	GTG	132;131;131	G;T;G	111;110;111	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	994	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2759	107.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1537	1539	GTG	132;131;131	G;T;G	111;110;111	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	994	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2759	107.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2041	2043	ACC	132;132;131	A;C;C,A	109;110;106,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	994	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2759	107.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2095	2097	GCG	128;129;129	G,A;C,G,T;G,C	102,1;91,1,1;97,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	994	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2759	107.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2095	2097	GCG	128;129;129	G,A;C,G,T;G,C	102,1;91,1,1;97,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	994	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2759	107.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2218	2220	GGC	137;137;137	G,C;G;C,T	110,1;117;114,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	994	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2759	107.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2227	2229	GGC	136;136;135	G,A,C;G,T;C	111,1,1;109,1;112	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	994	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2759	107.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2245	2247	CCG	130;130;130	C,T,G;C;G,T	108,1,1;108;107,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1474	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3534	124.8	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1764	1766	CTG	134;135;135	C;T;G	112;114;119	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	674	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2285	88.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	786	786	C	97	C	81	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	86	porB1a	984	171	90.29	porB1a.l15.c4.ctg.1	1418	17.4	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1272	1274	AAT	9;9;9	A;A;T	8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	86	porB1a	984	171	90.29	porB1a.l15.c4.ctg.1	1418	17.4	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1275	1277	AAT	9;9;9	A;A;T	8;8;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	86	porB1a	984	171	90.29	porB1a.l15.c4.ctg.1	1418	17.4	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1287	1289	GTT	9;9;9	G;T;T	8;8;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	86	porB1a	984	171	90.29	porB1a.l15.c4.ctg.1	1418	17.4	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1299	1301	GCA	9;9;9	G;C;A	8;6;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	86	porB1a	984	171	90.29	porB1a.l15.c4.ctg.1	1418	17.4	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1322	1324	GTA	9;9;9	G;T;A	8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	86	porB1a	984	171	90.29	porB1a.l15.c4.ctg.1	1418	17.4	0	.	p	.	0	D238fs	FSHIFT	712	712	G	1334	1334	G	9	G	8	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	770	porB1b	1035	1035	95.73	porB1b.l15.c4.ctg.1	1806	125.2	0	.	p	.	0	G50N	NONSYN	148	150	GGC	598	600	AAC	150;150;150	A,G;A,G;C,T	130,1;127,1;123,2	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	770	porB1b	1035	1035	95.73	porB1b.l15.c4.ctg.1	1806	125.2	0	.	p	.	0	F135L	NONSYN	403	405	TTT	853	855	CTT	141;142;142	C,G;T;T,G	127,1;125;124,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	770	porB1b	1035	1035	95.73	porB1b.l15.c4.ctg.1	1806	125.2	0	.	p	.	0	R143G	NONSYN	427	429	AGA	877	879	GGA	149;148;148	G,C;G,A;A,C	126,1;123,1;126,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	770	porB1b	1035	1035	95.73	porB1b.l15.c4.ctg.1	1806	125.2	0	.	p	.	0	D171G	NONSYN	511	513	GAT	961	963	GGT	148;147;146	G,T;G;T	127,1;126;125	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	770	porB1b	1035	1035	95.73	porB1b.l15.c4.ctg.1	1806	125.2	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1015	1017	AGC	156;155;157	A;G;C	129;131;132	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	770	porB1b	1035	1035	95.73	porB1b.l15.c4.ctg.1	1806	125.2	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1081	1081	T	154	T	129	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	770	porB1b	1035	1035	95.73	porB1b.l15.c4.ctg.1	1806	125.2	1	SNP	p	G120K	0	.	.	358	360	GGT	808	810	GGT	149;148;148	G,A;G,A;T,G	129,1;127,1;125,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	770	porB1b	1035	1035	95.73	porB1b.l15.c4.ctg.1	1806	125.2	1	SNP	p	A121N	0	.	.	361	363	GCC	811	813	GCC	147;147;147	G,A;C,A;C	126,1;123,1;131	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	770	porB1b	1035	1035	95.73	porB1b.l15.c4.ctg.1	1806	125.2	1	SNP	p	A121D	0	.	.	361	363	GCC	811	813	GCC	147;147;147	G,A;C,A;C	126,1;123,1;131	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2680	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5312	150.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2250	2252	AAT	171;171;171	A,C;A;T	148,1;144;144	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	406	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1312	91.8	1	SNP	p	V57M	1	.	.	169	171	ATG	672	674	ATG	154;154;154	A;T;G,T	127;130;133,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
